Loading…
Loading…
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage, for any covered stock.
TapClick below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
A year-by-year projected price path from the sell-side EPS consensus, with an editable target P/E and the implied annual return from today's price.
TapClick below to see what's inside, then upgrade to unlock for DD and 80,000+ other tickers.
See price against where its own fundamentals say it should trade. The shaded gap is the discount or premium, across five valuation lenses.
TapClick below to see what's inside, then upgrade to unlock for DD and 80,000+ other tickers.
See exactly how DD's revenue becomes profit: a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for DD and 80,000+ other tickers.
DuPont de Nemours, Inc. is a global provider of advanced materials and innovative solutions, serving markets across North America, Latin America, Europe, the Middle East, Africa, and the Asia Pacific region. The company's operations are organized into three primary segments: Electronics & Industrial, Mobility & Materials, and Water & Protection. The Electronics & Industrial division focuses on supplying critical materials and advanced systems. This includes products for the advanced printing sector and a comprehensive suite of materials and solutions essential for semiconductor and integrated…
DD expands its bioprocessing portfolio with AmberChrom SIL silica gel, targeting high-purity peptide purification amid growing demand for GLP-1 therapeutics.
New silica-based chromatography media helps biopharmaceutical manufacturers achieve demanding purity targets while supporting integrated purification workflows from crude purification through final polishing WILMINGTON, Del., Oct. 22, 2026 /PRNewswire/ -- DuPont (NYSE: DD) today announced the launch of DuPont™ AmberChrom™ SIL silica gel, a new reverse phase silica-based solution designed to support the purification and manufacture of peptide therapeutics, including glucagon-like peptide-1 ( GLP-1 ) receptor agonists.
Six industrial giants are selling off divisions while keeping payouts high, and the cash flow numbers behind those yields tell a very different story than the headline percentages suggest.
DuPont's innovation investments, healthcare acquisitions and productivity gains support growth as it raises 2026 earnings guidance amid persistent cost pressures.